Advertisement

Pharmacy World and Science

, Volume 17, Issue 4, pp 93–95 | Cite as

Bromocriptine and lactation suppression: Are the risks acceptable?

  • Lolkje de Jong-van den Berg
  • Barbara Mintzes
Editorial

Keywords

Adverse effects Bromocriptine Cardiovascular diseases Cerebrovascular diseases Incidence Lactation Product surveillance, postmarketing 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Herings RMC, Stricker BHC. Bromocriptine and suppression of postpartum lactation. The incidence of adverse cardiovascular effects in women of child-bearing age. Pharm World Sci 1995;17:133–7.PubMedGoogle Scholar
  2. 2.
    US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel); withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60:3404–5.Google Scholar
  3. 3.
    Health Canada, Drugs Directorate. Bromocriptine and lactation suppression. Can Adverse Drug React Newsletter 1995;5:66–7.Google Scholar
  4. 4.
    US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel) for the prevention of physiological lactation; opportunity for a hearing on a proposal to withdraw of approval of the indication. Fed Reg 1994;59:43347–52.Google Scholar
  5. 5.
    McCarthy M. Bromocriptine not for lactation suppression. Lancet 1994;344:602.Google Scholar
  6. 6.
    Rothman KJ, Funch DP, Dreyer NA. Bromocriptine and puerperal seizures. Epidemiology 1990; 1:232–8.PubMedGoogle Scholar
  7. 7.
    Watson DL, Bhatia RK, Norman GS, Brindley BA, Sokol RJ. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989;74:448–51.PubMedGoogle Scholar
  8. 8.
    Mallarkey G. Bromocriptine in lactation suppression: is there cause for concern? Curr Ther 1995:103–6.Google Scholar
  9. 9.
    Fournié A, Graile V, Montastruc JL. Bromocriptine, lactation inhibition and pharmacovigilance. J Gynecol Obstet Biol Reprod 1994;23:129–30.Google Scholar
  10. 10.
    Moride Y, Haramburu F, Bégaud B. Assessment of under-reporting of adverse events in pharmacovigilance. Pharmacoepidemiol Drug Saf 1994;3:S73.Google Scholar
  11. 11.
    Bromocriptine (Parlodel®) niet voor lactatieremming [Bromocriptine not for lactation suppression]. Geneesmiddelenbulletin 1994;28:84–5.Google Scholar
  12. 12.
    Zerebrale und kardiovaskulare Storwirkungen nach Abstillen met Bromocriptin (Pravidel). Arznei-telegramm 1995;3:27.Google Scholar
  13. 13.
    Mignot G. Inhibition de la lactation apres l'accounchement. Rev Prescrire 1995;15:440–5.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1995

Authors and Affiliations

  • Lolkje de Jong-van den Berg
    • 1
  • Barbara Mintzes
    • 2
  1. 1.Department of Social Pharmacy and Pharmacoepidemiology, Croningen Institute of Drug StudiesState University GroningenAW Groningenthe Netherlands
  2. 2.Health Action International EuropeNJ Amsterdamthe Netherlands

Personalised recommendations